Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms
NCT ID: NCT06803030
Last Updated: 2025-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
189 participants
INTERVENTIONAL
2025-08-30
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms
NCT04325880
Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms
NCT01880619
Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation
NCT03750656
Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms
NCT01457573
Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
NCT01741454
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tamsulosin group
placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily, to relieve the symptom
Tamsulosin Hydrochloride 0.4 mg
placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily
Solifenacin group
placement of ureteral stents followed by Tab Solifenacin 5 mg once daily, to relieve the symptom
Solifenacin Succinate 5 mg
placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily
Mirabegron group
placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily, to relieve the symptom
Mirabegron 25 mg
placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tamsulosin Hydrochloride 0.4 mg
placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily
Solifenacin Succinate 5 mg
placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily
Mirabegron 25 mg
placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Undergoing percutaneous nephrolithotomy, open ureteric surgery or laparoscopic ureteric surgery, including ureterolithotomy
* Neurogenic bladder, Over Active Bladder (OAB) syndrome, and neurological and psychiatric diseases
* Preoperative febrile Urinary Tract Infection (UTI)
* Pregnancy or breastfeeding;
* A single kidney
* Moderate or severe cardiovascular or cerebrovascular disease
* Hepatic dysfunction
* History of pelvic surgery or irradiation
* History of bladder or prostate surgery
* Other acute medical conditions (including acute pancreatitis, acute gastroenteritis, musculoskeletal disorders) that might influence the Ureteral Stent Symptom Questionnaire(USSQ) pain score
* Allergy to any medication
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nepal Health Research Council
OTHER_GOV
Bir Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jainendra Kumar Manoj
M Ch Urology Resident
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NAMS, Bir Hospital
Kathmandu, Bagmati, Nepal
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BirH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.